Eosinophilic syndrome with life-threatening end-organ damage

Shahd Ahmed, Erini V Kasfiki, John Smith

ABSTRACT

Introduction: Hypereosinophilic syndrome (HES) can be a multisystem disorder due to direct end-organ damage by eosinophilia, and can rarely present with life-threatening features. We present a case of multi-organ failure secondary to eosinophilia related to medications.

Case report: A 66-year-old woman with a recent diagnosis of asthma on montelukast, presented with excruciating pains of sudden onset in her lower limbs, and on admission, she was found to be in multi-organ failure. After initial resuscitation, immunological investigations, including vasculitic screen were negative, and hematological investigations revealed severe eosinophilia. She was diagnosed to have systemic eosinophilic granulomatosis polyarteritis secondary to montelukast. The agent was withdrawn and the patient was started on prednisolone. The initial symptom of severe pains preventing her from mobilizing was reversed within days and the patient was cured and become steroid free after six weeks of steroid treatment with no further problems reported in subsequent follow-up.

Conclusion: Eosinophilia may have a variety of causes, and montelukast is a recognized agent that can give rise to an eosinophilic syndrome. It can only be diagnosed once other systemic disorders have been excluded. The presentation can vary and can be multisystem, and rarely life-threatening, but it potentially is completely reversible, depending on the underlying diagnosis. In case of medications causing the syndrome, stopping the agent and giving a course of steroids may reverse the condition as in this case, without the need of immunotherapy in the long-term.
Eosinophilic syndrome with life-threatening end-organ
damage

Shahd Ahmed, Erini V Kasfiki, John Smith

ABSTRACT

Introduction: Hypereosinophilic syndrome (HES) can be a multisystem disorder due to direct end-organ damage by eosinophilia, and can rarely present with life-threatening features. We present a case of multi-organ failure secondary to eosinophilia related to medications. Case report: A 66-year-old woman with a recent diagnosis of asthma on montelukast, presented with excruciating pains of sudden onset in her lower limbs, and on admission, she was found to be in multi-organ failure. After initial resuscitation, immunological investigations, including vasculitic screen were negative, and hematological investigations revealed severe eosinophilia. She was diagnosed to have systemic eosinophilic granulomatosis polyarteritis secondary to montelukast. The agent was withdrawn and the patient was started on prednisolone. The initial symptom of severe pains preventing her from mobilizing was reversed within days and the patient was cured and become steroid free after six weeks of steroid treatment with no further problems reported in subsequent follow-up. Conclusion: Eosinophilia may have a variety of causes, and montelukast is a recognized agent that can give rise to an eosinophilic syndrome. It can only be diagnosed once other systemic disorders have been excluded. The presentation can vary and can be multisystem, and rarely life-threatening, but it potentially is completely reversible, depending on the underlying diagnosis. In case of medications causing the syndrome, stopping the agent and giving a course of steroids may reverse the condition as in this case, without the need of immunotherapy in the long-term.

Keywords: End-organ damage, Eosinophilia, Hypereosinophilic syndrome, Life-threatening vasculitis

Received: 21 November 2015
Accepted: 05 January 2016
Published: 01 April 2016

Eosinophilia refers to an absolute count of eosinophils >500/μl in the peripheral blood [1]. Hypereosinophilic syndrome is described when end-organ damage occurs directly because of eosinophilia, with other secondary causes having been excluded [2].
Patients may present with a variety of symptoms depending upon the end organ damage. In some patients the finding of eosinophilia is incidental, in others, as the patient described above, the initial manifestations may be severe or life-threatening.

We present a case of life-threatening hypereosinophilic syndrome secondary to medication use, which completely resolved on agent withdrawal.

CASE REPORT

A 66-year-old female presented with neuropathic pains across her right leg for two weeks. The patient had first noticed some paraesthesia on both lower limbs, which she described to feel like “pins and needles”, with a patchy distribution from her hips to her ankles. As the days progressed, the patient described excruciating shooting pains in all muscle groups in her right leg, to the point that on presentation she was unable to weight bear, and had to be wheeled into the department.

Her documented past medical history was mild asthma of late onset for a decade, and recently diagnosed mild gastritis and osteoarthritis.

The patient was on montelukast 10 mg once daily and lansoprazole 30 mg once daily.

On further questioning, she admitted to having had recurrent chest infections and asthma exacerbations over the last few months prior to her current presentation, requiring steroids and antibiotics every 2–3 weeks. For this purpose, she was under investigation by the respiratory team. A recent computed tomography scan of thorax revealed some post-infective scarring, with nothing else of note. She also admitted to mild weight loss and drenching sweats.

She was not diabetic, or anemic, and had no thyroid disease. She denied eye, skin, bowel, bladder, sinus or joint problems. She denied cigarette smoking or alcohol consumption, and she had no allergies to any medications.

On examination she was tachycardic, with a heart rate of 140 bpm, irregularly irregular, she was hypoxic and needed two liters of oxygen via nasal cannula to keep her oxygen saturations more than 94%. She was tachypneic with a respiratory rate of 22 beats per minute. She was apyrexial, and her blood pressure was stable.

On examination of her cardiovascular system, she had bilateral ankle pitting edema, her JVP was raised and her heart there were no murmurs.

On examination of her respiratory system, she was unable to talk in full sentences. On auscultation, she had bibasal reduced breathing sounds with dullness on percussion, but no wheeze. Her peak expiratory flow was 150, which was 75% of her normal.

Abdominal examination was unremarkable. She had no rashes, lymphadenopathy, or active synovitis.

Her GCS was 15/15, and pupils were equal and reactive to light and accommodation. Cranial nerve examination revealed no abnormalities, as did peripheral neurology examination of the upper limbs.

Examination of the lower limbs was limited due to pain. Power was 5/5 on the left leg, and equally reduced to 3/5 in all muscle groups, due to pain, on the right. Reflexes were globally reduced, and patient’s pain was intolerable when reflexes were tested. Vibration was normal, but proprioception was not formally assessed, as the patient had excruciating pains to even slight movement of her lower limb joints. The patient had obvious signs of small fiber neuropathy on the right lower limb.

Urine dipstick revealed proteinuria and hematuria.

The patient was adequately resuscitated with oxygen therapy and intravenous fluids, and analgesia was escalated to intravenous morphine, but with no success, as pain relief was not achieved. Routine investigations were sent. Thyroid function tests, immunoglobulin levels, complement levels, and creatine kinase were all normal. All electrolytes were within normal limits. Autoantibody screen, including ANCA, ANA and ENA, was negative. Hematinics, including vitamin B12 were normal. Liver and renal function were normal, as were clotting times. The only abnormal results from the bloods tested were her full blood count, her CRP and her serum IgE levels. The patient was anemic with hemoglobin of 10.8 g/dl (normocytic, normochromic), and her white cell count was raised to 25.2x10^9/L, with marked eosinophilia of 17.6 (x10^9/L). Her platelets were raised at 507x10^9/L. Her CRP was 120 (mg/L) (normal range 0-4 mg/L) and her IgE levels were 148 (U/L) (normal range <75U/L). Arterial blood gas was obtained, which revealed mild hypoxia. Chest X-ray revealed a small left sided pleural effusion (Figure 1).

A 12-lead ECG showed atrial fibrillation with fast ventricular response. Urgent echocardiogram showed moderate left ventricular hypertrophy, with pericardial effusion, but no echocardiographic signs of cardiac tamponade.

A diagnosis of systemic eosinophilic granulomatosis polyarteritis was made taking into account clinical and biochemical findings. The role of montelukast was questioned in the pathophysiology of the disease.

Montelukast was discontinued, amitriptyline and prednisolone were started at 25 mg and 40 mg daily respectively, and patient was put on bisoprolol and warfarin for her atrial fibrillation. DEXA scan was requested and alendronic acid was started prophylactically.

The patient’s symptoms of paraesthesia and leg pains completely resolved within the next days of this admission, and her eosinophils fell to 1.6x10^9/L within the first week of treatment. As such, nerve conduction studies and quantiferon test were both canceled, and further hematological advice was not sought.

Patient made partial recovery within three days, with only a patch of alloodynia on her right lateral malleolus, and full recovery within the next six weeks, with no further episodes of pain or further exacerbations of her asthma.
On further follow-up post-montelukast cessation and steroid withdraw, patient remained well and asymptomatic, with repeated bloods with normal blood count and eosinophilic values, having not required further treatment and in particular immunosuppression, making montelukast the main differential diagnosis for the patient’s life threatening presentation.

**DISCUSSION**

Eosinophilia may have a variety of causes, such as allergic and immunologic reactions, infectious diseases, hematological disorders, drug reactions, as DRESS syndrome, connective tissue disorders. The investigations should be targeting to identifying or excluding the above conditions, and also depend on the organs affected.

Searching though EMBASE and MEDLINE, in a combined search of the terms “eosinophilia” “montelukast” and “case report” reveals three previous case reports of montelukast associated eosinophilic syndrome in adults in English literature, which are dated from 2002 to 2012, none of which described an English patient [3–6]. However, this is the first case report in English literature that describes a case of eosinophilia with a clinically associated significant and life-threatening syndrome and negative ANCA antibody screen vasculitis.

The treatment, as in this case, encompasses of treating the manifestations of the different symptoms derived from the offended organs, cessation of the offending agent, and oral steroids at 1 mg/kg/day. In the case of eosinophilia due to an offending agent, as in the above patient, there is no evidence in the literature suggesting the time period between the cessation of the agent and the resolution of eosinophilia and its symptoms. Our patient’s symptoms started improving within the first day of montelukast cessation, even prior to starting high dose steroid treatment. The symptoms completely resolved and eosinophil number normalized within the next months.

What remains unexplained is the diagnosis of asthma prior to admission, which is the reason that the patient was started on montelukast in the first place. On subsequent follow-up, patient remained respiratory symptom free, with no variability of peak expiratory flow serial measurements and normal spirometry, and no further asthma treatment was required.

**CONCLUSION**

Hypereosinophilic syndrome can present with life-threatening multisystem involvement. Secondary causes, especially autoimmune and hematological conditions need to be excluded. Detailed drug history should be sought and offending agents must be stopped.

*******

**Author Contributions**

Shahd Ahmed – Group 1- Substantial contribution to conception and design, and acquisition of data, Group 2- Drafting the article, revising the article, Group 3- Final approval for publication

Eirini Kasfiki – Group 1- Substantial contribution to conception and design, and acquisition of data, Group 2- Drafting the article, revising the article, Group 3- Final approval for publication

John Smith – Group 1- Substantial contribution to conception and design, and acquisition of data, Group 2- Drafting the article, revising the article, Group 3- Final approval for publication

**Guarantor**

The corresponding author is the guarantor of submission.

**Conflict of Interest**

Authors declare no conflict of interest.

**Copyright**

© 2016 Shahd Ahmed, et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.
REFERENCES


Edorium Journals: An introduction

Edorium Journals Team

About Edorium Journals
Edorium Journals is a publisher of high-quality, open access, international scholarly journals covering subjects in basic sciences and clinical specialties and subspecialties.

Invitation for article submission
We sincerely invite you to submit your valuable research for publication to Edorium Journals.

But why should you publish with Edorium Journals?
In less than 10 words - we give you what no one does.

Vision of being the best
We have the vision of making our journals the best and the most authoritative journals in their respective specialties. We are working towards this goal every day of every week of every month of every year.

Exceptional services
We care for you, your work and your time. Our efficient, personalized and courteous services are a testimony to this.

Editorial Review
All manuscripts submitted to Edorium Journals undergo pre-processing review, first editorial review, peer review, second editorial review and finally third editorial review.

Peer Review
All manuscripts submitted to Edorium Journals undergo anonymous, double-blind, external peer review.

Early View version
Early View version of your manuscript will be published in the journal within 72 hours of final acceptance.

Manuscript status
From submission to publication of your article you will get regular updates (minimum six times) about status of your manuscripts directly in your email.

Our Commitment

Six weeks
You will get first decision on your manuscript within six weeks (42 days) of submission. If we fail to honor this by even one day, we will publish your manuscript free of charge.

Four weeks
After we receive page proofs, your manuscript will be published in the journal within four weeks (31 days). If we fail to honor this by even one day, we will publish your manuscript free of charge and refund you the full article publication charges you paid for your manuscript.

Most Favored Author program
Join this program and publish any number of articles free of charge for one to five years.

Favored Author program
One email is all it takes to become our favored author. You will not only get fee waivers but also get information and insights about scholarly publishing.

Institutional Membership program
Join our Institutional Memberships program and help scholars from your institute make their research accessible to all and save thousands of dollars in fees make their research accessible to all.

Our presence
We have some of the best designed publication formats. Our websites are very user friendly and enable you to do your work very easily with no hassle.

Something more...
We request you to have a look at our website to know more about us and our services.

We welcome you to interact with us, share with us, join us and of course publish with us.

CONNECT WITH US

Edorium Journals: On Web
Browse Journals

This page is not a part of the published article. This page is an introduction to Edorium Journals and the publication services.